Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-23-056184

Chief R&D Officer sold 9,646 shares at $0.49 ($4,727)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2023-11-17 Sale : show line 1 in the form −9,646 $0.49 $4,727 274,039 D
Open-market sales · 9,646 sh · avg $0.49 · $4,727
Loading xslF345X05/doc4.xml…